Education
About Us
Working with TipRanks
Follow Us
Personalis Inc (PSNL)
NASDAQ:PSNL
PSNL Stock Chart & Stats
$10.73
-$0.70(-11.71%)
At close: 4:00 PM EST
$10.73
-$0.70(-11.71%)
Day’s Range― - ―
52-Week Range$2.83 - $11.40
Previous CloseN/A
Volume738.16K
Average Volume (3M)1.56M
Market Cap
$952.87M
Enterprise Value$469.68M
Total Cash (Recent Filing)$150.51M
Total Debt (Recent Filing)$41.87M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Feb 19, 2026EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding88,804,350
10 Day Avg. Volume1,572,704
30 Day Avg. Volume1,559,399
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.69
Price to Sales (P/S)4.05
P/FCF Ratio-7.33
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue6.80
Enterprise Value/Gross Profit25.49
Enterprise Value/Ebitda-7.38
Forecast
1Y Price Target
$10.60Price Target Upside-1.21% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$70.35M
Bulls Say, Bears Say
Bulls Say
Medicare ReimbursementNeXT Personal received Medicare reimbursement for post-treatment monitoring for cancer recurrence in patients with stage II and III breast cancer.
Price Target IncreaseAnalyst adjusts the 12-month price target to $13, higher than the prior $10.
Revenue GrowthThe demand for NeXT Personal and clinical trial sample testing continues to grow.
Bears Say
MRD Approval DelaysThe company has now pushed their expected MRD MolDX approval timings twice in '25, with current guide calling for 2 approvals before YE, but does not include any revenue impact.
Revenue GuidanceManagement lowered their full year 2025 total revenue guidance range to $68M - $73M from prior $70M - $80M.
Stock Price ImpactThe stock sold off (~15%, on thin volumes) largely due to the reduced '25 guide, where 4Q revenues were guided (17%) below consensus.
Personalis News
PSNL FAQ
What was Personalis Inc’s price range in the past 12 months?
Personalis Inc lowest stock price was $2.83 and its highest was $11.40 in the past 12 months.
What is Personalis Inc’s market cap?
Personalis Inc’s market cap is $952.87M.
When is Personalis Inc’s upcoming earnings report date?
Personalis Inc’s upcoming earnings report date is Feb 19, 2026 which is in 79 days.
How were Personalis Inc’s earnings last quarter?
Personalis Inc released its earnings results on Nov 04, 2025. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.027.
Is Personalis Inc overvalued?
According to Wall Street analysts Personalis Inc’s price is currently Overvalued.
Does Personalis Inc pay dividends?
Personalis Inc does not currently pay dividends.
What is Personalis Inc’s EPS estimate?
Personalis Inc’s EPS estimate is -0.29.
How many shares outstanding does Personalis Inc have?
Personalis Inc has 88,804,350 shares outstanding.
What happened to Personalis Inc’s price movement after its last earnings report?
Personalis Inc reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -12.257%.
Which hedge fund is a major shareholder of Personalis Inc?
Currently, no hedge funds are holding shares in PSNL
Personalis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.60 (-1.21% Downside)
$10.60 (-1.21% Downside)
Blogger Sentiment
Bullish
PSNL Sentiment 66%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $266.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 3.2%
Last 30 Days ▲ 3.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
173.02%
12-Months-Change
Fundamentals
Return on Equity
-43.69%
Trailing 12-Months
Asset Growth
1.23%
Trailing 12-Months
Company Description
Personalis Inc
Personalis, Inc. is a biotechnology company based in the United States that specializes in genomics and precision medicine. The company focuses on providing advanced genomic sequencing services and bioinformatics solutions to aid in cancer research and treatment. Its core products include whole exome sequencing, tumor profiling, and other genomic analysis services aimed at enhancing the understanding of individual genetic profiles for personalized treatment options in oncology.
PSNL Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong clinical adoption and strategic partnerships, but also revealed significant revenue and margin challenges. While the company is confident in its clinical and reimbursement advancements, financial performance faced headwinds due to biopharma volatility and revenue declines.View all PSNL earnings summariesPSNL Stock 12 Month Forecast
Average Price Target
$10.60
▼(-1.21% Downside)
Technical Analysis
Ownership Overview
7.38% Insiders
7.84% Mutual Funds
35.24% Other Institutional Investors
33.80% Public Companies and
Individual Investors